SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Enthusiasm is building around $SLAP, with community members expressing bullish sentiment and highlighting its resilience in the current market. There's a strong sense of camaraderie among holders, who frequently use terms like $WAGMI (we're all gonna make it) and celebrate the project's unique branding and community engagement.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid broader crypto market volatility, with community members debating potential price movements and Elon Musk's influence. Discussions range from holding strategies to skepticism about future gains, with some anticipating a potential pump and others bracing for further consolidation. The potential launch of an ETF may be driving some optimism.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors digest the company's recent earnings, with some highlighting a narrower-than-expected loss and revenue growth. The community is actively discussing the potential impact of Rivian's AI and robotics initiatives, as well as upcoming catalysts like Autonomy Day. Despite some skepticism, optimism is fueled by Amazon's significant stake and hopes for the R2 model's success.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to community discussion around high borrow fees and potential short squeeze, as some retail investors report difficulty lending shares. Traders are debating the impact of dark pool trading and synthetic short positions, suggesting shorts are trapped and retail accumulation is key. Overall, the community is closely watching borrow rates, float size, and potential for a squeeze amid unusual trading activity.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amid mixed sentiment, with community members debating whether recent price movements are sustainable or just a "dead cat bounce." Some traders are pointing to potential catalysts like staking rewards and broader crypto market trends, while others warn of a possible downturn and label the token a "sucker coin."

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

ADUR is trending as the company progresses towards commissioning its pilot plant, aiming to validate its technology for converting waste into valuable resources. Community discussions revolve around the potential of Aduro's technology and its licensing model, with some comparing it favorably to competitors in the clean tech sector. Additionally, the stock's social media presence and marketing efforts are being closely watched.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending amid community discussion around its potential for growth and recent options activity. Some investors express frustration with the stock's recent performance despite analyst ratings, while others remain confident in the long-term vision and potential acquisitions led by Brad Jacobs. The community is actively discussing entry and exit points, with many expressing a bullish outlook.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer's pursuit of Metsera has intensified, with the company filing a second lawsuit against Novo Nordisk amidst a heated bidding war, driving significant community discussion around the potential acquisition's impact on the competitive landscape of obesity therapeutics. Community members are debating whether Pfizer is overpaying and if the acquisition aligns with their long-term strategy, especially given the existing competition in the weight loss market; at the same time, there's also discussion of Michael Burry's new position in PFE.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is trending as investors digest recent earnings and guidance, focusing on the impact of competition on Pylarify sales. Discussions revolve around management's strategy for navigating increased competition and the potential for acquisitions to drive future growth. The community is also weighing the significance of a recent share buyback program and leadership changes.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to a bidding war between PFE and NVO to acquire the company and its next-generation obesity pipeline. Community members discuss which company will ultimately win the deal and the potential implications for the broader obesity drug market. Some traders believe a competing bid could still emerge, further driving up the acquisition price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Health and Human Services Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee on Sept. 4 to discuss U.S. President Donald Trump’s healthcare agenda.Chairman Mike Crapo said the hearing will focus on “the Department of Health and Human Services’ Make America Healthy Again actions to date and plans moving forward,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/kennedy-testify-before-senate-panel-health-agenda-2025-08-28/">reported</a>.The session comes after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cdc-chief-susan-monarez-pushed-out-after-weeks-on-job-as-rfk-jr-overhauls-agency-she-s-fighting-back/chsCsP4Rdli">White House dismissed CDC Director Susan Monarez</a> on Wednesday, less than a month into her tenure. An associate said Monarez was fired after resisting vaccine policy changes advanced by Kennedy that she believed contradicted scientific evidence.&nbsp;Hours later, three senior officials — Chief Medical Officer Debra Houry, National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan — resigned and were&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/fired-cdc-director-clashed-with-kennedy-on-vaccine-policy-2025-08-28/">reportedly</a> escorted from the Atlanta campus.&nbsp;CDC staff, many wearing green shirts and ribbons as a sign of support, applauded them as they departed.Richard Besser, former acting CDC director, said Monarez told him she would not take any action that was illegal or “flew in the face of science,” and she refused to dismiss her leadership team without cause.&nbsp;The three departing officials said they resigned over anti-vaccine policies and misinformation promoted by Kennedy and his team. Daskalakis said, “I’m a doctor. I took the Hippocratic oath that said, ‘First, do no harm.’ I believe harm is going to happen, and so I can’t be a part of it.”Since taking office this year, Kennedy has fired the CDC’s vaccine advisory panel and replaced it with anti-vaccine activists and other advisers.&nbsp;He has made false claims about vaccines and launched an investigation into autism rates that he has linked, without evidence, to “environmental toxins.”&nbsp;The CDC has since dropped its recommendation that pregnant women be vaccinated against COVID and narrowed its guidance for children with health complications.White House spokeswoman Karoline Leavitt said Monarez was dismissed because she did not align with the president’s mission. “She said she would [resign], and then she said she wouldn’t, so the president fired her,” Leavitt said.&nbsp;Kennedy declined to comment on the specifics of the departures but told&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.foxnews.com/media/rfk-jr-warns-cdc-in-trouble-promises-fixes-director-refuses-step-down">Fox News</a>, “The agency is in trouble, and we need to fix it and we are fixing it. And it may be that some people should not be working there anymore.”&nbsp;Deputy HHS Secretary Jim O’Neill was named interim director of the CDC.Monarez’s dismissal is one of several recent moves by Trump to remove Senate-confirmed officials, including Federal Reserve Governor Lisa Cook and Surface Transportation Board member Robert Primus.On Stocktwits, retail sentiment was ‘bearish’ with ‘low’ message volume for both the iShares Biotechnology ETF (IBB) and the Health Care Select Sector SPDR Fund (XLV).While&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has been flat so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has risen 4.6% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit

The White House's move to oust Susan Monarez and the wave of senior CDC resignations have spotlighted deep divisions over vaccine policy and raised fresh questions about the administration’s healthcare agenda.

Equity

U.S. Centers for Disease Control and Prevention Director Susan Monarez has left the agency less than a month after being sworn in, amid the resignation of four senior officials&nbsp;who also resigned over vaccine policy tensions.Monarez’s attorneys said she is challenging her ouster, accusing HHS Secretary Robert F. Kennedy Jr. of targeting her for rejecting “unscientific directives,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-chief-exits-after-weeks-role-three-top-officials-resign-2025-08-27/">reported</a>.&nbsp;“Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign,” lawyers Mark S. Zaid and Abbe David Lowell said.The U.S. Department of Health and Human Services' account on X shared a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/HHSGov/status/1960818490614415869">post</a> about Monarez's exit, saying: "We thank her for her dedicated service to the American people. @SecKennedy has full confidence in his team at @CDCgov who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad."CDC Chief Medical Officer Debra Houry and Immunization Center Director Demetre Daskalakis have resigned, citing the rise in health misinformation, attacks on science, and budget cuts.&nbsp;Infectious Diseases Director Daniel Jernigan and Public Health Data Director Jen Layden also stepped down. Houry wrote that overstated risks and misinformation have fueled record measles cases and even a violent attack on the CDC.The White House’s 2026 budget proposed cutting CDC funding by $3.6 billion, while Kennedy had already eliminated 2,400 jobs and rehired 700. Daskalakis said he could not serve amid the “ongoing weaponizing of public health.”The CDC has faced mounting strain under Kennedy, including a shooting at its Atlanta headquarters. Former CDC official Fiona Havers called the latest resignations “devastating,” saying the departed leaders had shielded scientists from political attacks.Kennedy has rolled back vaccine policies, withdrawing COVID shot recommendations for children and pregnant women, and firing all members of the CDC vaccine advisory panel in June, replacing them with hand-picked advisers, including vaccine skeptics.&nbsp;On Wednesday, he announced further changes to COVID-19 vaccine eligibility and stated that autism policy announcements are expected in September.Monarez, a federal scientist, was confirmed on July 29 after being nominated by U.S. President Trump and sworn in by Kennedy on July 31. She succeeded Trump’s withdrawn pick, former congressman and vaccine critic Dave Weldon.&nbsp;On Stocktwits, retail sentiment was bearish for both the iShares Biotechnology ETF (IBB) with normal message volume, and the Health Care Select Sector SPDR Fund (XLV) with low message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has gained 4.9%, while&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has increased by 0.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monarez is a health scientist with a Ph.D. in microbiology and immunology who previously served as the Deputy Director of the Advanced Research Projects Agency for Health. (Photo by Kayla Bartkowski/Getty Images)

CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back

The sudden leadership shake-up at the CDC deepens turmoil inside the agency, where multiple senior officials have also resigned over vaccine policy disputes with Health Secretary Robert F. Kennedy Jr.

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient deaths involving the treatment.&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://stockwits.com/symbol/SRPT">Sarepta’s stock</a> plummeted more than 26% in midday trade on Friday. However, on Stocktwits, retail sentiment around the company remained in ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter.A separate&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-request-sarepta-stop-all-shipments-gene-therapy-elevidys-source-says-2025-07-18/#:~:text=The%20FDA's%20request%20follows%20the,condition%20called%20Duchenne%20muscular%20dystrophy.">report</a> by Reuters said that the FDA plans to request Sarepta to stop all shipments of Elevidys voluntarily.Makary’s comments during an&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/fda-is-investigating-if-sarepta-s-elevidys-should-stay-on-market">interview</a> with Bloomberg come after the company on Thursday disclosed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">third patient death</a> in a clinical trial involving a different experimental gene therapy that uses a similar viral delivery system.&nbsp;A company spokesperson&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.The FDA had already been investigating two earlier deaths linked to Elevidys.The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for gene treatments that use adeno-associated viral (AAV) vectors. Elevidys, which was granted accelerated approval in 2023 for Duchenne muscular dystrophy, has remained on the market under post-approval study requirements.Bloomberg also reported that the latest death resulted in an unusually tense exchange between analysts and Sarepta executives on a Friday call. The same group of analysts reportedly had a call with the company earlier this week about the future of Elevidys, but the firm failed to disclose the third patient death. On Friday, two of the analysts asked executives whether the company was keeping any other fatalities undisclosed.“We are historically a very transparent organization,” said Sarepta CEO Douglas Ingram, according to the report, adding that the company didn’t disclose the third patient death earlier because “it was neither material nor central” to what was being discussed.&nbsp;Sarepta’s stock is down 88% year-to-date and nearly 90% over the past 12 months.Get updates to this developing story directly on Stocktwits.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grubhub-owner-wonder-reportedly-in-talks-for-500-m-debt-refinancing/ch8kHoKR5qp">Grubhub Owner Wonder Reportedly In Talks For $500M Debt Refinancing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market

The FDA had already been investigating two earlier deaths linked to Elevidys.

Should You Invest in the VanEck Biotech ETF (BBH)?

BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBB News

IBBiShares Biotechnology ETF